Light J A, Biggers J A, Alijani M R, Smith M, Oddendino K
Proc Clin Dial Transplant Forum. 1980;10:67-73.
We have serially measured serum beta 2 M microglobulin in a series of transplant recipients along with other standard clinical parameters. Independent comparison of the beta 2 M results leads to the following conclusions: 1. Beta 2 M is superior to the Scr in detecting acute rejection, with diagnostic elevations occurring 2 to 7 days before Scr increase. The observation is valid for all rejection episodes. 2. Beta 2 M decreases prior to or simultaneously with the Scr following successful rejection therapy or beginning resolution of acute tubular necrosis. 3. Abnormal beta 2 M following rejection therapy invariably heralds another rejection episode within 10-20 days, despite the Scr having returned to baseline. 4. Beta 2 M remains normal in high grade ureteral obstruction despite increased Scr. 5. Beta 2 M is remarkably increased in patients with viremia, despite minimal change in Scr. Beta 2 M remains normal in lower UTI from bacterial origin. Beta 2 M appears to be a major contribution in the monitoring of the renal transplant recipient which may have significant impact on therapeutic decisions in the future. In addition, it provides a reliable in vitro parameter which can be used to further assess specific treatment variables in a prospective controlled protocol approach.
我们连续测量了一系列移植受者的血清β2微球蛋白以及其他标准临床参数。对β2微球蛋白结果进行独立比较得出以下结论：1. 在检测急性排斥反应方面，β2微球蛋白优于血清肌酐（Scr），诊断性升高出现在Scr升高前2至7天。该观察结果适用于所有排斥反应发作。2. 在成功进行排斥反应治疗后或急性肾小管坏死开始缓解时，β2微球蛋白在Scr之前或与之同时下降。3. 排斥反应治疗后β2微球蛋白异常总是预示着在10 - 20天内会再次发生排斥反应，尽管Scr已恢复到基线水平。4. 尽管Scr升高，但在重度输尿管梗阻时β2微球蛋白仍保持正常。5. 病毒血症患者的β2微球蛋白显著升高，尽管Scr变化极小。细菌性下尿路感染时β2微球蛋白保持正常。β2微球蛋白似乎对肾移植受者的监测有重要作用，可能会对未来的治疗决策产生重大影响。此外，它提供了一个可靠的体外参数，可用于以前瞻性对照方案方法进一步评估特定治疗变量。
